He makes 4500CR+ per year!| Unknown Side of Indian Medical Industry| Raw Talks Medical Podcast -41

TL;DR

The podcast discusses India’s fake drug problem and revolutionary changes in the medical industry.

Transcript

that is the biggest producer of fake drugs in the world and the most point medic First Medical podcast in with with Mr mad founder CEO of is the biggest disruptor and he's the best person to talk with 4,500 plus medical stores with over 10,000 cores of market cap and one of the top players in the medical industry I'm sure this will be another Maste... Read More

Key Insights

• 🤙 India is a significant contributor to the global issue of counterfeit drugs, representing 30% of the market, which calls for urgent reforms.
• 💊 Ethical practices and competitive pricing strategies are essential for genuine medicine distribution and growth in the pharmaceutical sector.
• ✋ The CEO's company focuses on technology to streamline operations, which positions them ahead of competitors and helps them maintain high standards.
• 💄 Generics are vital in making medications affordable, but their efficacy must be communicated effectively to alleviate public skepticism.
• 😫 The pharmaceutical industry is increasingly leveraging AI and automation, which are set to redefine operational efficiencies and market standards.
• ⛓️ Trust and transparency in supply chains will be crucial for regaining consumer confidence amid concerns over fake drugs.
• 😷 A strong network of reliable suppliers and a focus on quality assurance can significantly improve sales and market presence in the medical field.

Questions & Answers

Q: What percentage of fake drugs is produced in India, and why is it significant?

Approximately 30% of all fake drugs worldwide are produced in India, a concerning statistic that emphasizes the urgent need for reform in India's pharmaceutical sector. This problem not only affects the integrity of the healthcare system but also endangers patient safety. The CEO highlights the importance of quality control and ethical practices in ensuring genuine medication reaches consumers, which is essential for rebuilding trust in the market.

Q: How does the CEO plan to achieve a projected 20-22% growth in the company?

The CEO aims to achieve a projected growth target by reinforcing direct relationships with manufacturers, eliminating middlemen, and enhancing operational efficiencies. By obtaining discounts of 50-80% on medicines through strategic sourcing and robust internal systems, the company can offer competitive prices while ensuring product quality, thus expanding their customer base and market presence.

Q: What role does technology play in the future of the medical industry?

Technology is set to play a pivotal role in transforming the medical industry by improving efficiency and personalization in drug development. Innovations in biotechnology and artificial intelligence will enable quicker drug discovery, better patient care, and automated systems for inventory management, which hold the potential to revolutionize how medicines are produced and distributed.

Q: What advice does the CEO have for emerging entrepreneurs in the medical field?

The CEO emphasizes the importance of a unique selling proposition (USP) for startup entrepreneurs. They should focus on providing value by being cheaper, better, or faster than existing offerings. Additionally, understanding market opportunities thoroughly and surrounding oneself with knowledgeable investors is crucial for successful ventures in the competitive pharmaceutical landscape.

Summary & Key Takeaways

• The podcast features a discussion on the alarming statistics regarding fake drugs produced in India, which claims to account for 30% of global fakes. The necessity for genuine medication is underscored alongside the disruption needed in the industry.

• The CEO outlines significant growth targets for his company, projecting a 22% growth in turnover compared to the previous year, emphasizing the importance of ethical practices and effectiveness in managing the medical supply chain.

• The dialogue covers public skepticism about vaccines and the effectiveness of generic medicines, indicating a blend of personal experiences and broader industry challenges, including the impact of technology and future industry trends.